Health-care companies ticked up as investors rotated into defensive sectors less sensitive to the vagaries of Federal Reserve policy.
Biotech stocks gave back some of their recent gains. The iShares Nasdaq Biotechnology index exchange-traded fund, a basket of major biotech stocks, fell by roughly 1%, but is still up by more than 20% from its summer lows.
A creditor group that holds roughly $3.2 billion in Endo International debt is weighing a rival bid to purchase the drugmaker's assets out of chapter 11.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
08-19-22 1705ET
